Innovent Biologics, Inc. (IVBXF)
11.55
+0.55
(+5.00%)
USD |
OTCM |
Jan 08, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 19.74B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 155.0% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 12.16 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 82.96% |
Profile
| Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. It operates through the following geographical segments: The People's Republic of China (PRC), the United States of America (USA), and Indonesia. The company was founded by De Chao Yu, Kevin Chen, and Scott M. Wheelwright on April 28, 2011 and is headquartered in Suzhou, China. |
| URL | http://www.innoventbio.com |
| Investor Relations URL | N/A |
| HQ State/Province | Jiangsu |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 24, 2026 (est.) |
| Last Earnings Release | Aug. 27, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. It operates through the following geographical segments: The People's Republic of China (PRC), the United States of America (USA), and Indonesia. The company was founded by De Chao Yu, Kevin Chen, and Scott M. Wheelwright on April 28, 2011 and is headquartered in Suzhou, China. |
| URL | http://www.innoventbio.com |
| Investor Relations URL | N/A |
| HQ State/Province | Jiangsu |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 24, 2026 (est.) |
| Last Earnings Release | Aug. 27, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |